Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

被引：202

作者：

Pal, Sumanta K. ^{[1
]}

Rosenberg, Jonathan E. ^{[2
]}

Hoffman-Censits, Jean H. ^{[3
]}

Berger, Raanan ^{[4
]}

Quinn, David I. ^{[5
]}

Galsky, Matthew D. ^{[6
]}

Wolf, Juergen ^{[7
]}

Dittrich, Christian ^{[8
]}

Keam, Bhumsuk ^{[9
]}

Delord, Jean-Pierre ^{[10
]}

Schellens, Jan H. M. ^{[11
]}

Gravis, Gwenaelle ^{[12
]}

Medioni, Jacques ^{[13
]}

Maroto, Pablo ^{[14
]}

Sriuranpong, Virote ^{[15
,16
]}

Charoentum, Chaiyut ^{[17
]}

Burris, Howard A. ^{[18
]}

Grunwald, Viktor ^{[19
]}

Petrylak, Daniel ^{[20
]}

Vaishampayan, Ulka ^{[21
]}

Gez, Eliahu ^{[22
]}

De Giorgi, Ugo ^{[23
]}

Lee, Jae-Lyun ^{[24
]}

Voortman, Jens ^{[25
]}

Gupta, Sumati ^{[26
]}

Sharma, Sunil ^{[26
]}

Mortazavi, Amir ^{[27
]}

Vaughn, David J. ^{[28
]}

Isaacs, Randi ^{[29
]}

Parker, Katie ^{[29
]}

Chen, Xueying ^{[29
]}

Yu, Kun ^{[30
]}

Porter, Dale ^{[30
]}

Porta, Diana Graus ^{[31
]}

Bajorin, Dean F. ^{[2
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

[3] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[4] Chaim Sheba Med Ctr, Ramat Gan, Israel

[5] USC Norris Canc Ctr, Los Angeles, CA USA

[6] Mt Sinai Hosp, New York, NY 10029 USA

[7] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany

[8] Kaiser Franz Josef Spital, ACR ITR VIEnna, Appl Canc Res Inst Translat Res Vienna, Vienna, Austria

[9] Seoul Natl Univ Hosp, Seoul, South Korea

[10] IUCT Oncopole, Toulouse, France

[11] Netherlands Canc Inst, Amsterdam, Netherlands

[12] Inst Paoli Calmettes, Marseilles, France

[13] Hop Europeen Georges Pompidou, Paris, France

[14] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[15] Chulalongkorn Univ, Fac Med, Bangkok, Thailand

[16] King Chulalongkorn Mem Hosp, Bangkok, Thailand

[17] Maharaj Nakorn Chiangmai Hosp, Chiang Mai, Thailand

[18] Sarah Cannon Res Inst, Nashville, TN USA

[19] Clin Hematol Hemostasis Oncol & Stem Cell Transp, Med Sch Hannover, Hannover, Germany

[20] Yale Sch Med, New Haven, CT USA

[21] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[22] Tel Aviv Sourasky Med Ctr Ichilov, Tel Aviv, Israel

[23] Inst Sci Romagnolo Studio & Cura Tumori IRST IRC, Meldola, Italy

[24] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[25] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Amsterdam, Netherlands

[26] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[27] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[28] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[29] Novartis Pharmaceut, E Hanover, NJ USA

[30] Novartis Inst BioMed Res, Cambridge, MA USA

[31] Novartis Pharma AG, Basel, Switzerland

来源：

CANCER DISCOVERY | 2018年 / 8卷 / 07期

关键词：

CISPLATIN-INELIGIBLE PATIENTS; ACQUIRED-RESISTANCE; GENETIC ALTERATIONS; BLADDER-CANCER; SINGLE-ARM; MULTICENTER; PEMBROLIZUMAB; NVP-BGJ398; MUTATIONS;

D O I：

10.1158/2159-8290.CD-18-0229

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 87 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation, and decreased appetite. Further examination of BGJ398 in this disease setting is warranted. SIGNIFICANCE: BJG398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease. (C) 2018 AACR.

引用

页码：812 / 821

页数：10

共 50 条

[31] Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
Javle, M.
Kelley, R. K.
Roychowdhury, S.
Weiss, K. H.
Abou-Alfa, G. K.
Macarulla, T.
Sadeghi, S.
Waldschmidt, D.
Zhu, A. X.
Goyal, L.
Borad, M.
Yong, W. P.
Borbath, I.
El-Khoueiry, A.
Philip, P.
Moran, S.
Ye, Y.
Ising, M.
Lewis, N.
Bekaii-Saab, T.
ANNALS OF ONCOLOGY, 2018, 29 : 720 - 720
[32] Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma
Soria, J-C.
Italiano, A.
Cervantes, A.
Tabernero, J.
Infante, J.
Lara, P. N.
Spira, A.
Calvo, E.
Moreno, V.
Blay, J-Y.
Lauer, R.
Chan, N.
Zhong, B.
Santiago-Walker, A. Ademi
Bussolari, J.
Luo, F. R.
Xie, H.
Hammerman, P.
ANNALS OF ONCOLOGY, 2016, 27
[33] Genomic analysis of fibroblast growth factor receptor 3 (FGFR3) in multiple myeloma patients.
Onwuazor, ON
Xiao, YW
Ding, YW
Shaughnessy, JD
Stewart, AK
BLOOD, 2002, 100 (11) : 391A - 392A
[34] Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
Meric-Bernstam, F.
Arkenau, H.
Tran, B.
Bahleda, R.
Kelley, R.
Hierro, C.
Ahn, D.
Zhu, A.
Javle, M.
Winkler, R.
He, H.
Huang, J.
Goyal, L.
ANNALS OF ONCOLOGY, 2018, 29
[35] Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: Evaluation of tumor tissue and response at a single center.
Nogova, Lucia
Malchers, Florian
Bitter, Elisabeth
Michels, Sebastian Yves Friedrich
Fischer, Rieke Nila
Scheffler, Matthias
Gardizi, Masyar
Brandes, Vanessa
Scheel, Andreas H.
Kambartel, Karl -Otto
Krueger, Stefan
Serke, Monika Heidi
Isaacs, Randi
Porter, Dale
Buettner, Reinhard
Thomas, Roman K.
Wolf, Juergen
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[36] Fibroblast growth factor receptor 3 (FGFR3) mutation in an extensive epidermal naevus
Collin, B.
Taylor, I. B.
Wilkie, A. C. M.
Moss, C.
BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 : 8 - 9
[37] Human epidermal growth factor receptor 2 (HER2) and fibroblast growth factor receptor 3 (FGFR3) mutations to reveal biological pathways in urothelial carcinoma.
Chu, Carissa Ellen
Escano, Manuel De Jesus
Yip, Wesley
Jiang, Song
Iyer, Gopa
Al-Ahmadie, Hikmat A.
Goh, Alvin C.
Dalbagni, Guido
Bochner, Bernard H.
Solit, David B.
Pietzak, Eugene J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[38] Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
Al-Ahmadie, Hikmat A.
Iyer, Gopa
Janakiraman, Manickam
Lin, Oscar
Heguy, Adriana
Tickoo, Satish K.
Fine, Samson W.
Gopalan, Anuradha
Chen, Ying-bei
Balar, Arjun
Riches, Jamie
Bochner, Bernard
Dalbagni, Guido
Bajorin, Dean F.
Reuter, Victor E.
Milowsky, Matthew I.
Solit, David B.
JOURNAL OF PATHOLOGY, 2011, 224 (02): : 270 - 279
[39] Developmental expression of splicing variants of fibroblast growth factor receptor 3 (FGFR3) in mouse
Wuechner, C
Nordqvist, ACS
Winterpacht, A
Zabel, B
Schalling, M
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY, 1996, 40 (06): : 1185 - 1188
[40] Fibroblast growth factor receptor 3 (FGFR3) expression in non-hodgkin lymphoma
Larson, A.
Cook, J. R.
MODERN PATHOLOGY, 2007, 20 : 249A - 250A

← 1 2 3 4 5 →